

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

Acetaminophen for Chronic Pain in Pediatric Populations: Clinical Effectiveness

Service Line: Rapid Response Service
Version: 1.0
Publication Date: May 19, 2020
Report Length: 6 Pages

Authors: Shannon Hill, Andrea Ryce

Cite As: Acetaminophen for chronic pain in pediatric populations: clinical effectiveness. Ottawa: CADTH; 2020 May. (CADTH rapid response report: summary of abstracts).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Research Question

What is the clinical effectiveness of acetaminophen for the treatment of chronic pain in pediatric patients?

Key Findings

One overview of systematic reviews and two systematic reviews were identified regarding the clinical effectiveness of acetaminophen for the treatment of chronic pain in pediatric patients.

Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE and EMBASE via OVID, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were acetaminophen and pediatric chronic pain. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2015 and May 5, 2020. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	Pediatric patients with chronic pain, including pain from chronic daily headaches, migraines, back pain, abdominal pain, idiopathic local pain, chronic widespread pain and fibromyalgia, and complex regional pain syndrome
Intervention	Acetaminophen (paracetamol)
Comparator	Other pharmacological medications (e.g., gabapentin, pregabalin, amitriptyline, nortriptyline, duloxetine, ibuprofen, naproxen, ketorolac) Placebo Non-pharmacological interventions (e.g., physiotherapy, exercise, counseling, neurostimulation)
Outcomes	Clinical effectiveness (e.g., change in pain symptoms, change in quality of life, functional outcomes, disability)
Study Designs	Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies

Results

One overview of systematic reviews¹ and two systematic reviews^{2,3} were identified regarding the clinical effectiveness of acetaminophen for the treatment of chronic pain in pediatric patients. No relevant health technology assessments, randomized controlled trials, or non-randomized studies were identified.

Additional references of potential interest that did not meet the inclusion criteria are provided in the appendix.

Overall Summary of Findings

One overview of systematic reviews¹ and two systematic reviews^{2,3} were identified regarding the clinical effectiveness of acetaminophen (also commonly referred to as paracetamol) for the treatment of chronic pain in pediatric patients. The authors of the identified overview of systematic reviews evaluated acetaminophen and ibuprofen for treating pain in children.¹ The authors found supporting evidence in one of the systematic reviews regarding safety outcomes for acetaminophen use.¹ Additionally, the systematic reviews reporting on efficacy and adverse events for acetaminophen and ibuprofen had no overall conclusion regarding effectiveness.¹ The second identified study was a systematic review regarding the efficacy and adverse events of acetaminophen use for chronic non-cancer pain in children.² The authors found no evidence that was considered eligible for inclusion in the systematic review and therefore no conclusion could be made regarding the use of acetaminophen for the treatment of chronic non-cancer pain in children.² The last identified study was a systematic review which examined pharmacological interventions versus placebo for migraine treatment in children.³ Acetaminophen was identified in one primary study, however, the authors reported that acetaminophen was not superior to placebo for migraine symptom relief.³

References Summarized

Health Technology Assessments

No literature identified.

Overview of Systematic Reviews

1. Radman M, Babic A, Runjic E, et al. Revisiting established medicines: an overview of systematic reviews about ibuprofen and paracetamol for treating pain in children. *Eu J Pain*. 2019 Jul;23(6):1071-1082.
[PubMed: PM30793444](#)

Systematic Reviews

2. Cooper TE, Fisher E, Anderson B, Wilkinson NM, Williams DG, Eccleston C. Paracetamol (acetaminophen) for chronic non-cancer pain in children and adolescents. *Cochrane Database Syst Rev*. 2017;8:CD012539.
[PubMed: PM28770975](#)
3. Richer L, Billingham L, Linsdell MA, et al. Drugs for the acute treatment of migraine in children and adolescents. *Cochrane Database Syst Rev*. 2016 Apr 19;4:CD005220.
[PubMed: PM27091010](#)

Randomized Controlled Trials

No literature identified.

Non-Randomized Studies

No literature identified.

Appendix — Further Information

Previous CADTH Report

4. Dosing recommendations for acetaminophen in pediatrics: clinical review and guidelines. Ottawa (ON): CADTH; May 2008; <https://cadth.ca/dosing-recommendations-acetaminophen-pediatrics-clinical-review-and-guidelines>
Accessed 2020 May 19.

Systematic Reviews

Population Not Specified in Abstract

5. Le May S, Ali S, Khadra C, et al. Pain management of pediatric musculoskeletal injury in the emergency department: a systematic review. *Pain Res Manag.* 2016;2016:4809394.
[PubMed: PM27445614](#)

Outcomes Not Specified in Abstract

6. Barnes NP. Migraine headache in children. *BMJ Clin Evid.* 2015 Jun 05;pii:0318.
[PubMed: PM26044059](#)

Randomized Controlled Trials

Alternative Population

7. Luo S, Ran M, Luo Q, et al. Alternating acetaminophen and ibuprofen versus monotherapies in improvements of distress and reducing refractory fever in febrile children: a randomized controlled trial. *Paediatr Drugs.* 2017 Oct;19(5):479-486.
[PubMed: PM28523589](#)
8. Sheehan WJ, Mauger DT, Paul IM, et al. Acetaminophen versus ibuprofen in young children with mild persistent asthma. *N Engl J Med.* 2016 Aug 18;375(7):619-630.
[PubMed: PM27532828](#)

Review Article

9. Kacperski J, Hershey AD. Newly approved agents for the treatment and prevention of pediatric migraine. *CNS Drugs.* 2016 09;30(9):837-844.
[PubMed: PM27503180](#)